2563 Stock Overview
A synthetic biology-driven biopharmaceutical company, engages in the research and development, production, and commercialization of oncology products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Beijing Biostar Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$28.90 |
| 52 Week High | HK$30.05 |
| 52 Week Low | HK$19.48 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 38.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2563 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -0.2% | -0.3% | -0.6% |
| 1Y | n/a | -15.2% | 9.6% |
Return vs Industry: Insufficient data to determine how 2563 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2563 performed against the Hong Kong Market.
Price Volatility
| 2563 volatility | |
|---|---|
| 2563 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2563's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 2563's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Rongguo Qiu | www.biostar-pharm.com |
Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research and development, production, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of metastasis breast cancer, advanced non-small cell lung cancer, solid tumor, and Glioblastoma. It also engages in the development of Utidelone oral capsule that is in phase II/III clinical trials; Utidelone nano formulation; and Utidelone antibody drug conjugate, as well as other active pharmaceutical ingredients, such as BG22, BG18 and BG44.
Beijing Biostar Pharmaceuticals Co., Ltd. Fundamentals Summary
| 2563 fundamental statistics | |
|---|---|
| Market cap | HK$10.54b |
| Earnings (TTM) | -HK$203.75m |
| Revenue (TTM) | HK$71.59m |
147.2x
P/S Ratio-51.7x
P/E RatioIs 2563 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2563 income statement (TTM) | |
|---|---|
| Revenue | CN¥66.64m |
| Cost of Revenue | CN¥19.81m |
| Gross Profit | CN¥46.83m |
| Other Expenses | CN¥236.47m |
| Earnings | -CN¥189.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 70.27% |
| Net Profit Margin | -284.60% |
| Debt/Equity Ratio | 0% |
How did 2563 perform over the long term?
See historical performance and comparison